SCHEMBL22354571

SCHEMBL22354571

OC(COCCCCOCC(O)CN1CCOCC1)CN1CCOCC1

nearest known ligand 0.62

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
USP2 O75604 3/20 0.62
SMN1; SMN2 Q16637 2/20 0.51
L3MBTL1 Q9Y468 1/20 0.51
GAA P10253 3/20 0.50
MAPK1 P28482 1/20 0.50
POLB P06746 1/20 0.50
ALDH1A1 P00352 2/20 0.49
TSHR P16473 3/20 0.49
HTT P42858 1/20 0.48
PKM P14618 1/20 0.48
KDM4E B2RXH2 1/20 0.47
ALOX15 P16050 1/20 0.47
ADRB2 P07550 2/20 0.46
ADRB1 P08588 2/20 0.46
ADRB3 P13945 2/20 0.46
KMT2A Q03164 2/20 0.46
CYP1A2 P05177 1/20 0.46
CYP2C19 P33261 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20487113 0.93 USP2 (0.67) USP2SMN1; SMN2L3MBTL1GAAMAPK1
SCHEMBL12761114 0.90 USP2 (0.59) USP2SMN1; SMN2L3MBTL1GAAMAPK1
SCHEMBL12153680 0.84 ALDH1A1 (0.49) USP2SMN1; SMN2L3MBTL1GAAMAPK1
SCHEMBL16707883 0.84 USP2 (0.47) USP2SMN1; SMN2L3MBTL1GAAMAPK1
SCHEMBL15025122 0.83 USP2 (0.55) USP2SMN1; SMN2L3MBTL1GAAMAPK1
SCHEMBL1245084 0.83 USP2 (0.46) USP2SMN1; SMN2L3MBTL1GAAMAPK1
SCHEMBL21301880 0.82 USP2 (0.53) USP2SMN1; SMN2L3MBTL1GAAMAPK1
SCHEMBL14076168 0.82 USP2 (0.62) USP2SMN1; SMN2L3MBTL1GAAMAPK1
SCHEMBL15536318 0.82 USP2 (0.45) USP2SMN1; SMN2L3MBTL1GAAMAPK1
SCHEMBL14116865 0.81 USP2 (0.67) USP2SMN1; SMN2L3MBTL1GAAMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230159581-A1 NOVEL ANTI-INFECTIVE AND ANTI-INFLAMMATORY COMPOUNDS SYNOVO GMBH (DE) 2023-05-25 US disclosed
US-20230159581-A1 NOVEL ANTI-INFECTIVE AND ANTI-INFLAMMATORY COMPOUNDS SYNOVO GMBH (DE) 2023-05-25 US disclosed
US-20230131943-A1 ANTI-INFECTIVE AND ANTI-VIRAL COMPOUNDS AND COMPOSITIONS BURNET MICHEAL W (DE) 2023-04-27 US disclosed
US-20230131943-A1 ANTI-INFECTIVE AND ANTI-VIRAL COMPOUNDS AND COMPOSITIONS BURNET MICHEAL W (DE) 2023-04-27 US disclosed
US-20200262857-A1 NOVEL ANTI-INFECTIVE AND ANTI-INFLAMMATORY COMPOUNDS SYNOVO GMBH (DE) 2020-08-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230131943-A1 ANTI-INFECTIVE AND ANTI-VIRAL COMPOUNDS AND COMPOSITIONS CTSA, GAA, SLC7A5 USP2 571/4885SMN1; SMN2 2710/4885L3MBTL1 1536/4885
US-20230159581-A1 NOVEL ANTI-INFECTIVE AND ANTI-INFLAMMATORY COMPOUNDS CTSA, ALOX15, ALOX5 USP2 928/4885SMN1; SMN2 3489/4885L3MBTL1 1562/4885
US-20200262857-A1 NOVEL ANTI-INFECTIVE AND ANTI-INFLAMMATORY COMPOUNDS CTSA, ALOX15, ALOX5 USP2 928/4885SMN1; SMN2 3489/4885L3MBTL1 1562/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.